InterCure Ltd

InterCure Ltd(INCR)股票分析

$5.510

-0.239 (-4.34%)收盤時

Loading chart…
High
5.790
Open
5.790
VWAP
5.59
Vol
10.81K
Mkt Cap
89.78M
Low
5.475
Amount
60.46K
EV/EBITDA, TTM
0.00

InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets.

AI analysis of InterCure Ltd (INCR)

buy

InterCure Ltd is a good buy right now due to its current price of 5.78, a significant 5-day change of +35.76%, and strong financial backing from a recent settlement of approximately $77 million. The main risk is its negative 1-year change of -29.08%, indicating past performance issues that investors should consider.

Analyst Ratings (12)

Buy
8 Buy
4 Hold
0 Sell
Current: 5.51
最低
平均
最高

TD Cowen

2023-04-12

目標價

$5

Buy

Barclays

2017-12-11

目標價

Hold

Credit Suisse

2017-11-14

目標價

Buy

Keybanc

2017-11-13

目標價

Buy

Baird

2017-11-10

目標價

Buy

估值指標

The current forward P/E ratio for InterCure Ltd (INCR) is 6.18, compared to its 5-year average forward P/E of 0.54.

Forward P/E

Strongly Overvalued
5Y Average P/E
0.54
Current P/E
6.18
高估
3.33
低估
-2.24

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-1.29
Current EV/EBITDA
0.00
高估
10.99
低估
-13.56

Forward P/S

Undervalued
5Y Average P/S
1.16
Current P/S
0.00
高估
1.97
低估
0.34

事件時間軸

2026-08-24 (ET)

07:30:00

InterCure Reaches $77M Settlement with Israeli Tax Authorities

2026-08-21 (ET)

20:00:00

INC Research Trading Halted, News Pending

2026-03-03 (ET)

17:00:00

InterCure Receives Nasdaq Compliance Notice

2026-02-19 (ET)

07:10:00

InterCure Expects Positive EBITDA for 2025

2025-11-03 (ET)

08:38:59

InterCure and Cannasoul Forge Strategic Investment and Collaboration Partnerships

資訊

INCR FAQ — answered by Alphio AI

InterCure Ltd. is an Israel-based company engaged in the medical cannabis industry. Through its wholly owned subsidiary, Canndoc Ltd., the Company cultivates, produces, processes, markets, and distributes medical cannabis products. Its operations include the development and manufacture of pharmaceutical-grade medical cannabis products produced in accordance with Good Manufacturing Practice (GMP) standards. The Company offers a range of cannabis-based products for medical use and operates across various stages of the medical cannabis value chain, including cultivation, manufacturing, logistics, distribution, and retail activities. In addition, the Company is involved in the import, export, and commercialization of medical cannabis products and related healthcare solutions in Israel and selected international markets. It operates in the Healthcare sector.

InterCure Ltd is a good buy right now due to its current price of 5.78, a significant 5-day change of +35.76%, and strong financial backing from a recent settlement of approximately $77 million. The main risk is its negative 1-year change of -29.08%, indicating past performance issues that investors should consider.

12 analysts cover INCR: 8 rate it Buy, 4 Hold and 0 Sell.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始